Grifols A : Q2 2021 earnings to reflect difficult plasma supply but good underlying demand trends
>Q2 2021 numbers due on 29 July - Grifols will publish its Q2 2021 results on 29 July: We expect Q2 2021 numbers still to be affected by the plasma shortage (primary raw material) on fewer donors visiting plasma collection centres although the year-on-year comparison will be favoured this time by the € 185m one-off costs included in Q2 2020 related to the lower value of the inventories due to the COVID-19 impact.Results to be affected by difficult plasma...Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.